ERC Einstein Rockefeller CUNY Center for AIDS Research

ERC 爱因斯坦洛克菲勒纽约市立大学艾滋病研究中心

基本信息

  • 批准号:
    10458264
  • 负责人:
  • 金额:
    $ 72.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-05-01 至 2027-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY ERC-CFAR: CLINICAL AND TRANSLATIONAL SCIENCE CORE (CTSC) To help meet the vision of Ending the HIV Epidemic (EHE), the Einstein-Rockefeller-CUNY Center for AIDS Research (ERC-CFAR) has formed strong collaborations both within and beyond our partner institutions, including the New York City Department of Health and Mental Hygiene, to catalyze and support research that best serves the public’s health: to eradicate HIV infection, prevent new HIV infections, and improve the health of people living with HIV (PWH). The overarching goal of the ERC-CFAR and the Clinical and Translational Science Core (CTSC) is to support the EHE mission by creating a broad and robust resource available to researchers within our walls as well as nationally and globally. Our synergistic partnership provides a broad range of support for clinical, translational, health services, and implementation science investigations. By leveraging the resources of the Einstein CTSA-funded Institute for Clinical and Translational Research, the CTSC provides access to a robust clinical database and multiple biorepositories. The Clinical Cohort Database (CCDB), derived from the Montefiore/Einstein clinical services, has ~20,000 PWH and 475,000 HIV-negative patients; >6200 PWH are in active care; 43% are women, 48% Hispanic/Latinx and 41% African American. This comprehensive, longitudinal database accesses Montefiore’s extensive clinical infrastructure and has fostered an explosion of clinical prevention and treatment, epidemiologic, translational, health services and implementation science research. We facilitate enrollment of well-characterized patients (including HIV-negative controls) into new research protocols. Through CTSC resources the clinical population at Montefiore/Einstein enables research at Rockefeller, which lacks access to defined cohorts of PWH, recruiting new participants for Rockefeller’s cutting-edge research in HIV eradication. The City University of New York (CUNY) is a leader in implementation science assessing the factors that influence our ability to impact favorably on the public’s health with interventions of proven efficacy. The CTSC is integrated into the Scientific Working Group, a driver of the ERC-CFAR’s scientific direction, to provide optimal support to the emerging research activities, and foster cross- fertilization among cores and the SWG. We will leverage Einstein’s Center for Health Data Innovations and use of state-of-the-art informatics methods, including natural language processing and machine learning, to catalyze and facilitate new research in primary prevention of HIV infection, while maintaining our extensive support of well-established research areas.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kathryn M. Anastos其他文献

Kathryn M. Anastos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kathryn M. Anastos', 18)}}的其他基金

Rwanda CASCADE Clinical Trials Site for cervical cancer prevention
卢旺达 CASCADE 宫颈癌预防临床试验基地
  • 批准号:
    10757692
  • 财政年份:
    2023
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
  • 批准号:
    10414093
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/ Malignancies
爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟
  • 批准号:
    10267220
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
  • 批准号:
    10267222
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
  • 批准号:
    10267223
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/ Malignancies
爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟
  • 批准号:
    10654706
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
  • 批准号:
    10654712
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
  • 批准号:
    10084653
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
  • 批准号:
    10084655
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/Malignancies
爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟
  • 批准号:
    10654699
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 72.38万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 72.38万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 72.38万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 72.38万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 72.38万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 72.38万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 72.38万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 72.38万
  • 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
  • 批准号:
    03660315
  • 财政年份:
    1991
  • 资助金额:
    $ 72.38万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 72.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了